Clinical Trials Browser

milademetan × Clear all

NCT01877382 2025-03-27

A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas

Phase 1 Completed

107 enrolled 29 charts

Lymphoma

NCT04979442 2025-01-14

MANTRA

Phase 3 Terminated

175 enrolled 16 charts

Liposarcoma, Sarcoma

NCT05012397 2024-10-17

Milademetan in Advanced/Metastatic Solid Tumors

Phase 2 Terminated

40 enrolled 13 charts

DermatologicEndocrineGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Testicular Germ Cell Tumor, Adenocarcinoma of Lung, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Adrenocortical Carcinoma, Cholangiocarcinoma

NCT05932667 2023-12-21

DEMETER

Phase 2 Terminated

Breast Neoplasms

NCT03671564 2023-11-07

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1 Completed

14 enrolled 14 charts

Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Phase 1/2 Withdrawn

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT03552029 2022-05-20

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Phase 1 Terminated

10 enrolled 10 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02319369 2021-10-11

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 1 Terminated

74 enrolled 30 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute